All In Biotech

Drug Trial Radar · NCT07377838

Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ADSTEM Inj. for Moderate to Severe Subacute and Chronic Atopic Dermatitis Patients

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Sep 2029

Study completion Dec 2029

Sponsor

Lead sponsor
EHL Bio Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis

Conditions

  • Atopic Dermatitis

Interventions

  • ADSTEM Inj.Biological

    hAD-MSC 1.0x10\^8 cells

  • PlaceboDrug

    0.9% Normal Saline Inj.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who achieve a score of 0 or 1 on the validated Investigator's Global Assessment (vIGA) scale at Visit 6, and demonstrate at least a 2-point reduction from baseline(Visit 2)Time frame: From baseline to Weeks 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Soonchunhyang University Cheonan Hospital

    Cheonan, Chungcheongnam-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.